Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02867800 · ClinicalTrials.gov registry record · Phase 1

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

A Phase 1 study of Sickle Cell Disease and Graft-Versus-Host Disease, sponsored by Monica Bhatia.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
7
Study locations

NCT02867800 is a Phase 1 study of Sickle Cell Disease and Graft-Versus-Host Disease that has completed, run by Monica Bhatia. The registered enrollment target is 24 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02867800, a Phase 1 study of Sickle Cell Disease and Graft-Versus-Host Disease, has completed, sponsored by Monica Bhatia.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
7
Study locations

Study Summary

To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine, thiotepa, melphalan, and alemtuzumab for conditioning.

Conditions Studied

Sickle Cell Disease Graft-Versus-Host Disease

Interventions

  • DRUG Acetaminophen
  • DRUG Alemtuzumab
  • DRUG Methylprednisolone
  • DRUG Diphenhydramine
  • DRUG Meperidine

Study Locations (7)

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Massachusetts

  • Floating Hospital for Children at Tufts Medical Center - Boston

New York

  • Columbia University Irving Medical Center - New York

North Carolina

  • North Carolina Cancer Hospital - Chapel Hill

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-07
Est. Completion 2023-12-30
Phase Phase 1

Sponsor

Monica Bhatia

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02867800

The ClinicalTrials.gov registry entry for NCT02867800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (92% lower). The listed sponsor is Monica Bhatia, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.

NCT02867800 reports 7 study locations spanning 7 distinct geographic areas - top geographies include District of Columbia, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT02867800 about?

NCT02867800 is a clinical study titled "Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease". To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine, thiotepa, melphalan, and al...

What is the current status of trial NCT02867800?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-07. Estimated completion is 2023-12-30.

What conditions does trial NCT02867800 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Graft-Versus-Host Disease.

What interventions are being tested in trial NCT02867800?

The interventions under investigation include: Acetaminophen (DRUG), Alemtuzumab (DRUG), Methylprednisolone (DRUG), Diphenhydramine (DRUG), Meperidine (DRUG).

Who is sponsoring clinical trial NCT02867800?

This trial is sponsored by Monica Bhatia, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02867800 being conducted?

This trial has 7 study locations across District of Columbia, Georgia, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Graft-Versus-Host Disease

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.